UBS keeps EUR 300.00 target for Sartorius stock

Published on 10/16/2026 at 16:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius was valued at EUR 17.9 billion on October 16, 2026. Sartorius stock costs EUR 258.35 on October 16, 2026, down 1.32 percent versus its Xetra close.

Analyst view shapes market context

UBS maintained a Buy rating and a EUR 300.00 target in its October 14, 2026 study.
Sartorius was valued at EUR 17.9 billion on October 16, 2026.
Sartorius stock costs EUR 258.35 at Lang & Schwarz on October 16, 2026 at 4:08 p.m. CEST, 1.32 percent below the Xetra close of October 15, 2026.
Sartorius traded at a price-to-earnings ratio of 91.34 on October 16, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) carries a EUR 300.00 target from UBS, 16.12 percent above the quoted price. In a study dated October 14, 2026, Ariva reported that UBS kept its Buy rating ahead of the October 22 results. Sartorius stock was trading at EUR 258.35 at Lang & Schwarz on October 16, 2026 at 4:08 p.m. CEST, down 1.32 percent versus the Xetra close of October 15, 2026 at EUR 261.80.

Results date is October 22, 2026

The next scheduled reporting event is the third-quarter update on October 22, 2026. Sartorius' investor-relations page lists a conference call for the nine-month 2026 results at 1:00 p.m. CEST on that date, giving the market a defined near-term calendar point. The page also identifies Sartorius as a supplier of bioprocess and laboratory solutions for the biopharmaceutical industry.

Range spans EUR 198.50 to EUR 271.90

The 52-week range runs from EUR 198.50 to EUR 271.90 as of October 16, 2026. The Lang & Schwarz bid was EUR 258.20 and the ask EUR 258.50 at 4:08 p.m. CEST, while reported volume for the Xetra listing stood at 21,319 shares at 4:05 p.m. CEST. The current price was 4.98 percent below the 52-week high, leaving the stock below its recent peak despite the analyst target above the market price.

Valuation and market comparison

Sartorius had a market capitalization of EUR 17.9 billion on October 16, 2026, and traded at a price-to-earnings ratio of 91.34. The 16.12 percent gap between the UBS target and the Lang & Schwarz price is a valuation marker, not a forecast from this report.

Comparison with peers

Sartorius: minus 1.32 percent, P/E 91.34, market capitalization EUR 17.9 billion
Merck KGaA (Xetra, EUR): plus 0.24 percent, P/E 26.36, market capitalization EUR 62.4 billion
Danaher (NYSE, USD): minus 1.02 percent, P/E 40.73, market capitalization USD 161.1 billion

Stock price and investor perspective

The combination of a EUR 300.00 analyst target, a scheduled October 22 report and a EUR 17.9 billion market value gives investors three concrete reference points for the next session. The price remains 4.98 percent below its 52-week high.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.